A Novel Phenotype of GCK c.781G>A Variant Causing Neonatal Refractory Hyperinsulinaemic Hypoglycaemia

Clicks: 3
ID: 314117
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #98 of 114 articles by views in qjm : monthly journal of the association of physicians

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Glucokinase (GCK) mutations are well-known causes of maturity-onset diabetes of the young type 2 (MODY2) and hyperinsulinaemic hypoglycaemia type 3 (HH3). The GCK c.781G>A (p.Gly261Arg) variant has been exclusively reported in MODY2. We describe a term male infant with severe refractory neonatal hypoglycaemia and inappropriately elevated insulin. Genetic analysis identified a heterozygous GCK c.781G>A variant inherited from his father. Protein modelling supported a gain-of-function effect. The infant responded well to diazoxide and discontinued treatment two weeks after discharge. This is the first report of GCK c.781G>A presenting as neonatal HH3, expanding the known phenotypic spectrum of this variant.
Reference Key
openalex_W7161712214 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jianfeng Lin, Yiqun He
Journal qjm : monthly journal of the association of physicians
Year 2026
DOI
10.1093/qjmed/hcag128
URL
https://doi.org/10.1093/qjmed/hcag128
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.